Browse drugs

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…TEZO, atezolizumab; BINI, binimetinib; COBI, cobimetinib; ENCO, encorafenib; ESS, effective sample size; DAB, dabrafenib; NIVO, nivolumab; …

…follow-up.Conclusions Our findings indicate that Dabrafenib and cetuximab with chemotherapy are effective and tolerable first-line and se…

…suggesting that DC inclusion dampens the macrophage response to bemcentinib.9 Separation of macrophages by A375 state was further reflected…

…esponses including autophagy (figure 2C). Finally, single agent encorafenib was administered in the 3rd and 4th line in two patients with l…

…participation in the trial. Standard therapies considered were: pembrolizumab (adjuvant, high risk stage II–IV melanoma); dabrafenib + tramet…

…f care (26.3%). 31.5% of patients required a dose adjustment of binimetinib, and 21% discontinued treatment, with only one discontinuation …

…(NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vem…

…05755Thomas SS, Gogas H, Hong YK, et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and …

…) had lung metastases. The most frequently prescribed TKIs were cabozantinib (n=31), dabrafenib (n=25), and lenvatinib (n=17). 48% of patien…